Sulfasalazine

This product contains sulfasalazine.

1. When used with urine alkalinizing drugs, the solubility of sulfonamides in alkaline urine can be enhanced, which increases excretion. 2. Para-aminobenzoic acid can replace sulfonamides and be taken up by bacteria, antagonizing the antibacterial effect of sulfonamides. Therefore, the two should not be used together. 3. When the following drugs are used in combination with sulfonamides, the latter can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, when these drugs are used in combination with sulfonamides, or after the use of sulfonamides, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. When bone marrow suppressive drugs are used in combination with sulfonamides, the adverse reactions of such drugs to the hematopoietic system may be enhanced. If there is an indication that the two types of drugs need to be used together, the possible toxic reactions should be closely observed. 5. Contraceptives (estrogens), long-term use with sulfonamides can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When thrombolytic drugs are used in combination with sulfonamides, their potential toxic effects may be increased. 7. When hepatotoxic drugs are used in combination with sulfonamides, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drugs for a long time and have a history of liver disease. 8. When photosensitizing drugs are used in combination with sulfonamides, additive photosensitization may occur. 9. Patients receiving sulfonamide treatment have an increased need for vitamin K. 10. Hexamethylenetetramine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with sulfonamides. This increases the risk of crystalluria, so the two drugs should not be used in combination. 11. Sulfonamides can replace the plasma protein binding site of phenylbutazone, and when the two are used in combination, the effect of phenylbutazone can be enhanced. 12. When sulfinpyrazone is used in combination with sulfonamides, the latter can reduce the latter's secretion from the renal tubules, and its blood drug concentration increases and lasts for a long time, thus producing toxicity. Therefore, the dosage of sulfonamides may need to be adjusted during or after the use of sulfinpyrazone. When the course of sulfinpyrazone is long, the blood concentration of sulfonamides should be monitored to help adjust the dosage and ensure safe use. 13. When used in combination with digitalis or folic acid, the latter's absorption is reduced and the blood concentration is reduced, so the effect and efficacy of digitalis must be observed at any time. 14. When used in combination with probenecid, it will reduce the excretion of sulfonamides in the renal tubules, causing the blood concentration of sulfonamides to increase, the effect is prolonged, and it is easy to be poisoned. 15. When used in combination with neomycin, neomycin inhibits intestinal flora, affects the decomposition of this product in the intestine, and reduces its effect.

The main ingredient of this product is sulfasalazine; its chemical name is 5-[p-(2-pyridylaminesulfonyl)phenyl]azosalicylic acid.

1. Combination with urine alkalinizing drugs can enhance the solubility of sulfonamides in alkaline urine and increase excretion. 2. Para-aminobenzoic acid can replace sulfonamides and be taken up by bacteria, antagonizing the antibacterial effect of sulfonamides. Therefore, the two should not be used together. 3. When the following drugs are used in combination with sulfonamides, the latter can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, when these drugs are used in combination with sulfonamides, or when used after the application of sulfonamides, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium, and thiopental sodium. 4. Myelosuppressive drugs, when used in combination with sulfonamides, may enhance the effects of such drugs on the hematopoietic system.

The main ingredient of this product is sulfasalazine, and its chemical name is: 5-[p-(2-pyridylaminesulfonyl)phenyl]azosalicylic acid.

1. Combination with urine alkalinizing drugs can enhance the solubility of sulfonamides in alkaline urine and increase excretion. 2. Para-aminobenzoic acid can replace sulfonamides and be taken up by bacteria, antagonizing the antibacterial effect of sulfonamides. Therefore, the two should not be used together. 3. When the following drugs are used in combination with sulfonamides, the latter can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, when these drugs are used in combination with sulfonamides, or when used after the application of sulfonamides, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium, and thiopental sodium. 4. Myelosuppressive drugs, when used in combination with sulfonamides, may enhance the effects of such drugs on the hematopoietic system.